Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593680 | 0.86 | HTT (0.32) | ACACBACACA | |
| SCHEMBL2428376 | 0.83 | TSHR (0.35) | TSHR | |
| SCHEMBL30575792 | 0.83 | FDPS (0.43) | FDPSLMNATSHRFFAR4FFAR1 | |
| SCHEMBL29232764 | 0.83 | FDPS (0.43) | FDPSLMNATSHRFFAR4FFAR1 | |
| SCHEMBL28568549 | 0.83 | FDPS (0.43) | FDPSLMNATSHRFFAR4FFAR1 | |
| SCHEMBL15855762 | 0.83 | FDPS (0.43) | FDPSLMNATSHRFFAR4FFAR1 | |
| SCHEMBL1328891 | 0.83 | FDPS (0.43) | FDPSLMNATSHRFFAR4FFAR1 | |
| SCHEMBL412444 | 0.80 | LMNA (0.40) | FDPSLMNATSHRFFAR4FFAR1 | |
| SCHEMBL6286014 | 0.80 | LMNA (0.40) | FDPSLMNATSHRFFAR4FFAR1 | |
| SCHEMBL22249 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176817-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176817-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | GRHPR, AGXT, GLS2 | FDPS 1731/4885LMNA 1299/4885TSHR 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.